Abstract
Arterial thrombosis, venous thrombosis and morbidity during pregnancy, or a combination of these events, are clinical outcomes associated with antiphospholipid antibodies produced by patients with antiphospholipid syndrome (APS). Our understanding of the etiology and pathogenesis of the syndrome is limited, but it has generally been considered a thrombophilic disease and treatment has focused on anticoagulation. Agents such as aspirin and heparin, administered alone or in combination, are empirical treatments that are used in the management of obstetric patients with APS. Clinical features, such as heart valve abnormalities, thrombocytopenia and livedo reticularis, suggest multiple pathogenic mechanisms and provide other therapeutic targets. Findings from research in animal models of APS challenge the dogma that this syndrome is a noninflammatory, thrombotic disease and provide evidence that activation of complement is crucial for complications in pregnancy. These studies, in addition to evidence of inflammatory-mediated tissue damage in placentae of patients with APS, suggest that therapy should also be directed towards preventing inflammation. This Review describes the potential mechanisms of tissue injury by antiphospholipid antibodies, the management of pregnant patients with APS and how heparin therapy might inhibit the pathogenic mediators of disease.
Key Points
-
Antiphospholipid syndrome is characterized by thrombosis and morbidity during pregnancy, or a combination of these events, in association with antiphospholipid antibodies
-
Heparin, at subanticoagulant doses, and low-dose aspirin regimens are thought to reduce the risk of spontaneous pregnancy loss in patients with antiphospholipid syndrome
-
In a mouse model of antiphospholipid syndrome, pregnancy complications are initiated by complement-mediated inflammation, rather than by thrombosis
-
Treatment with heparin prevents complement activation and protects mice from pregnancy complications induced by antiphospholipid antibodies, whereas other anticoagulants are not protective
-
Heparins might prevent obstetric complications in women with antiphospholipid syndrome because of their anti-inflammatory effects
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wilson WA et al. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42: 1309–1311
Miyakis S et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295–306
McNeil HP et al. (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87: 4120–4124
Galli M et al. (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335: 1544–1547
Matsuura E et al. (1990) Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336: 177–178
Stephenson MD (1996) Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril 66: 24–29
Del Papa N et al. (1997) Endothelial cells as a target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 40: 551–561
Simantov R et al. (1995) Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 96: 2211–2219
Zhou H et al. (2004) Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 104: 2353–2358
Raschi E et al. (2003) Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101: 3495–3500
Ma K et al. (2000) High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 275: 15541–15548
Lutters BC et al. (2003) Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem 278: 33831–33838
Rand JH and Wu XX (2004) Antibody-mediated interference with annexins in the antiphospholipid syndrome. Thromb Res 114: 383–389
Atsumi T et al. (2005) Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies. Autoimmunity 38: 377–381
Di Simone N et al. (2000) Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 43: 140–150
Derksen RH et al. (2004) Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 50: 1028–1039
Holers VM et al. (2002) Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 195: 211–220
Girardi G et al. (2003) Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112: 1644–1654
Pierangeli SS et al. (2005) Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 52: 2120–2124
Xu C et al. (2000) A critical role for murine complement regulator crry in fetomaternal tolerance. Science 287: 498–501
Mao D et al. (2003) Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. Immunity 19: 813–822
Stone S et al. (2006) The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 27: 457–467
Quenby S et al. (2005) Recurrent miscarriage and long-term thrombosis risk: a case-control study. Hum Reprod 20: 1729–1732
Le Thi Thuong D et al. (2005) The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 64: 273–278
Buyon JP et al. (1999) Assessing disease activity in SLE patients during pregnancy. Lupus 8: 677–684
Magid MS et al. (1998) Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol 179: 226–234
Salafia CM and Cowchock FS (1997) Placental pathology and antiphospholipid antibodies: a descriptive study. Am J Perinatol 14: 435–441
La Rosa L et al. (1994) Beta 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome. J Rheumatol 21: 1684–1693
Ross G et al. (2003) Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med 157: 397–402
Neri F et al. (2004) Neuropsychological development of children born to patients with systemic lupus erythematosus. Lupus 13: 805–811
Empson M et al. (2005) Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. The Cochrane Database of Systematic Reviews, Issue 2, Art. No CD002859
Lassere M and Empson M (2004) Treatment of antiphospholipid syndrome in pregnancy--a systematic review of randomized therapeutic trials. Thromb Res 114: 419–426
Cowchock FS et al. (1992) Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 166: 1318–1323
Silver RK et al. (1993) Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 169: 1411–1417
Kutteh WH (1996) Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174: 1584–1589
Rai R et al. (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314: 253–257
Farquharson RG et al. (2002) Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 100: 408–413
Ensom MH and Stephenson MD (2004) Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy. J Soc Gynecol Investig 11: 377–383
Noble LS et al. (2005) Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 83: 684–690
Stephenson MD et al. (2004) Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 26: 729–734
Tincani A et al. (2003) Treatment of pregnant patients with antiphospholipid syndrome. Lupus 12: 524–529
Sibai BM et al. (2003) What we have learned about preeclampsia. Semin Perinatol 27: 239–246
Duley L et al. (2004) Antiplatelet agents for preventing pre-eclampsia and its complications. The Cochrane Database of Systematic Reviews, Issue 1, Art. No CD004659
Bose P et al. (2005) Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 192: 23–30
Lockshin MD et al. (1989) Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 160: 439–443
Carp H et al. (2001) Intravenous immunoglobulin in pregnancies complicated by the antiphospholipid antibody. J Clin Rheumatol 7: 291–294
Triolo G et al. (2004) IVIG in APS pregnancy. Lupus 13: 731–735
Branch DW et al. (2000) A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 182: 122–127
McCrae KR (2003) Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis, and management. Blood Rev 17: 7–14
Koenig A et al. (1998) Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 101: 877–889
Wang L et al. (2002) Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 110: 127–136
Wan MX et al. (2001) Low molecular weight heparin inhibits tumor necrosis factor alpha-induced leukocyte rolling. Inflamm Res 50: 581–584
Lash GE et al. (2003) Vascular endothelial growth factor is a chemoattractant for trophoblast cells. Placenta 24: 549–556
Di Simone N et al. (2006) Low-molecular Weight Heparin Induces In Vitro Trophoblast Invasiveness: Role of Matrix Metalloproteinases and Tissue Inhibitors. Placenta [doi:10.1016/j.placenta.2006.04.001]
Hamatani T et al. (2004) Global gene expression analysis identifies molecular pathways distinguishing blastocyst dormancy and activation. Proc Natl Acad Sci USA 101: 10326–10331
Franklin RD and Kutteh WH (2003) Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol 101: 455–462
Wagenknecht DR and McIntyre JA (1992) Interaction of heparin with beta 2-glycoprotein I and antiphospholipid antibodies in vitro. Thromb Res 68: 495–500
Guerin J et al. (2002) Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol Chem 277: 2644–2649
Ecker E and Gross P (1929) Anticomplementary Power of Heparin. J Infect Dis 44: 250
Loos M et al. (1976) Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement-III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry 13: 789–791
Weiler JM et al. (1978) Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J Exp Med 147: 409–421
Kazatchkine MD et al. (1981) Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 67: 223–228
Ninomiya H et al. (2000) Inhibition of complement-mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low-molecular weight heparin. Br J Haematol 109: 875–881
Girardi G et al. (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10: 1222–1226
Buyon JP et al. (1992) Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum 35: 55–61
Abramson SB and Buyon JP (1992) Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. Am J Reprod Immunol 28: 183–187
Lockshin MD et al. (1985) Lupus pregnancy. II. Unusual pattern of hypocomplementemia and thrombocytopenia in the pregnant patient. Arthritis Rheum 28: 58–66
Buyon JP et al. (1986) Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. Am J Med 81: 194–200
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Salmon, J., Girardi, G. & Lockshin, M. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Rev Rheumatol 3, 140–147 (2007). https://doi.org/10.1038/ncprheum0432
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0432
This article is cited by
-
Pregnancy in patients with systemic lupus erythematosus: a systematic review
Archives of Gynecology and Obstetrics (2022)
-
Inflammatory markers in thrombosis associated with primary antiphospholipid syndrome
Journal of Thrombosis and Thrombolysis (2020)
-
Emerging Therapies in Antiphospholipid Syndrome
Current Rheumatology Reports (2016)
-
PROMISSE: progress in understanding pregnancy complications in patients with SLE
Arthritis Research & Therapy (2012)
-
The Clinical Significance of Coagulation and the Inflammatory Response in Autoimmunity
Clinical Reviews in Allergy & Immunology (2012)